Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting isocitrate dehydrogenase (IDH) in cancer.

Discovery medicine - 1 May 2016

Fujii Takeo, Khawaja Muhammad Rizwan, DiNardo Courtney D, Atkins Johnique T, Janku Filip

Abstract excerpt

Isocitrate dehydrogenase (IDH) is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. Recurrent mutations in IDH1 or IDH2 are prevalent in several cancers including glioma, acute myeloid leukemia (AML), cholangiocarcinoma and chondrosarcoma. The mutated IDH1 and IDH2 proteins have a gain-of-function, neomorphic activity, catalyzing the reduction of α-ketoglutarate (α-KG) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Respiration
Share to Clinical Trials as Topic
Share to Glutarates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Demethylases

Share to Isocitrate Dehydrogenase

Share to Ketoglutaric Acids

Share to Molecular Targeted Therapy

Source

Identifiers

PMID: 27355333

Genes

IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting isocitrate dehydrogenase (IDH) in cancer.PMID 27355333Read ↗

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future PerspectivesSemantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Semantic proximity Read ↗

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.